N-Terminus Urea-Substituted Chemotactic Peptides: New Potent Agonists and Antagonists toward the Neutrophil fMLF Receptor
John Higgins(Massachusetts General Hospital), Howard F. Solomon, Michael J. Abrams(Rapt Therapeutics (United States)), Michael J. Beblavy(Massachusetts General Hospital), Gary Bridger, Pedro E. Hernandez(Massachusetts General Hospital), Forrest E. Gaul(Massachusetts General Hospital), Marilyn C. Pike(Bethesda Hospital), Claudia K. Derian(Johnson & Johnson (United States))
Cited by 43
Related Papers
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
|Blood|2003|717
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
|Circulation|2002|652
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
|Blood|2008|481
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
|Annals of the Rheumatic Diseases|2013|340
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure
|Kidney International|1999|305